Remibrutinib (blinded)

DRUG2 trials

Sponsors

Novartis Pharmaceuticals

Conditions

Generalized Myasthenia GravisSecondary Progressive Multiple Sclerosis (SPMS)

Phase 3

A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis

RecruitingNCT06744920

Novartis PharmaceuticalsGeneralized Myasthenia Gravis

Start: 2025-02-07End: 2033-02-26Target: 180Updated: 2026-07-29

A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis

RecruitingNCT07225504

Novartis PharmaceuticalsSecondary Progressive Multiple Sclerosis (SPMS)

Start: 2025-11-11End: 2034-01-02Target: 1275Updated: 2026-07-29